Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVX-B1
- Development stage
- Preclinical
- Lead developer
- Evaxion Biotech
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EVX-B1 is a preclinical-stage protein subunit vaccine developed by Evaxion Biotech for the prevention and treatment of *Staphylococcus aureus* (*S. aureus*) infections, including skin and soft tissue infections (SSTI). The vaccine is designed using Evaxion's proprietary AI platform, EDIVAC, to identify and target specific toxins and virulence factors of the bacteria. By inducing an immune response against these critical components, EVX-B1 aims to neutralize the pathogen's ability to cause disease and evade the host immune system.
02
Targets
PVL (Panton–Valentine leukocidin)
Beyond the preview
Go deeper on EVX-B1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVX-B1.